Latest News and Events
Filter by
Selections
December 21, 2022
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Read MoreDecember 21, 2022
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
Read MoreDecember 20, 2022
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Read MoreDecember 15, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreDecember 8, 2022
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Read MoreNovember 21, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Read MoreNovember 9, 2022